Wei Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wei Guo has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Cheng Wu
Department of Health Statistics, Second Military Medical University, Shanghai, China
2 shared publications - Jia He
Department of Health Statistics, Naval Medical University, Shanghai, China
2 shared publications - Yuchen Qin
Department of Health Statistics, Second Military Medical University, Shanghai, China
2 shared publications - Bo Jin
Senior Department of Hepatology, The Fifth Medical Center of PLA General Hospital, Beijing 100039, China
1 shared publication - Cheng Yang
The Department of Orthopedic Oncology, Shanghai Changzheng Hospital, Second Affiliated Hospital of Naval Medical University, Shanghai, China
1 shared publication - Chenglong Zhao
Second Military Medical University
1 shared publication
Latest Publications
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (19) , 1822-1832
Efficacy and Safety of Camrelizumab Plus Apatinib in Patients With Refractory Chordoma: A Phase II Clinical Trial
PURPOSE: Limited efficacy of current treatments for chordoma calls for novel therapeutic options. Combination of immune checkpoint inhibitors and antiangiogenic drugs has altered the landscape of cancer treatment but has rarely been investigated in chordoma. METHODS: An investigator-initiated, single-center, phase II trial was conducted on camrelizumab (a PD-1 inhibitor, 200 mg once every 2 weeks) plus apatinib (an antiangiogenic drug, 250 mg and 500 mg on alternate days, that is, 250 mg one day, 500 mg the next day, alternating) in patients with refractory chordoma for 4-week cycles. The primary end point was the objective response rate (ORR) per RECIST version 1.1. Secondary end points included ORR per Choi criteria, progression-free survival (PFS), overall survival, the disease control rate, median duration of response (mDoR), safety, and quality of life. The trial is registered with Chictr.org.cn (ChiCTR2100042938). RESULTS: Of the 38 patients initially screened between September 2021 and October 2024, 33 were enrolled. Median follow-up duration was 20.8 months (IQR, 13.35-26.55). ORR was 24.2% (8/33 [95% CI, 11.1 to 42.3]) per RECIST 1.1 and 48.5% (16/33 [95% CI, 30.8 to 66.5]) per Choi criteria. The median PFS was 28.4 months (95% CI, 13.53 to 43.28). The mDoR was not reached per RECIST 1.1 and was 22.2 months (95% CI, 12.5 to not reached) per Choi criteria. CDKN2A copy-number deletion or homozygous deletion was found to associate with worse prognosis. The most common grade 3 or 4 treatment-related adverse events included increased aspartate aminotransferase (13 [39.4%]) and increased alanine aminotransferase (11 [33.3%]). No treatment-related deaths occurred. CONCLUSION: Combination of camrelizumab and apatinib offered encouraging efficacy with manageable toxicity in chordoma treatment. CDKN2A alterations are associated with worse prognosis and may prove to be a potential biomarker for treatment selection.
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (19) , 1822-1832
Efficacy and Safety of Camrelizumab Plus Apatinib in Patients With Refractory Chordoma: A Phase II Clinical Trial
PURPOSE: Limited efficacy of current treatments for chordoma calls for novel therapeutic options. Combination of immune checkpoint inhibitors and antiangiogenic drugs has altered the landscape of cancer treatment but has rarely been investigated in chordoma. METHODS: An investigator-initiated, single-center, phase II trial was conducted on camrelizumab (a PD-1 inhibitor, 200 mg once every 2 weeks) plus apatinib (an antiangiogenic drug, 250 mg and 500 mg on alternate days, that is, 250 mg one day, 500 mg the next day, alternating) in patients with refractory chordoma for 4-week cycles. The primary end point was the objective response rate (ORR) per RECIST version 1.1. Secondary end points included ORR per Choi criteria, progression-free survival (PFS), overall survival, the disease control rate, median duration of response (mDoR), safety, and quality of life. The trial is registered with Chictr.org.cn (ChiCTR2100042938). RESULTS: Of the 38 patients initially screened between September 2021 and October 2024, 33 were enrolled. Median follow-up duration was 20.8 months (IQR, 13.35-26.55). ORR was 24.2% (8/33 [95% CI, 11.1 to 42.3]) per RECIST 1.1 and 48.5% (16/33 [95% CI, 30.8 to 66.5]) per Choi criteria. The median PFS was 28.4 months (95% CI, 13.53 to 43.28). The mDoR was not reached per RECIST 1.1 and was 22.2 months (95% CI, 12.5 to not reached) per Choi criteria. CDKN2A copy-number deletion or homozygous deletion was found to associate with worse prognosis. The most common grade 3 or 4 treatment-related adverse events included increased aspartate aminotransferase (13 [39.4%]) and increased alanine aminotransferase (11 [33.3%]). No treatment-related deaths occurred. CONCLUSION: Combination of camrelizumab and apatinib offered encouraging efficacy with manageable toxicity in chordoma treatment. CDKN2A alterations are associated with worse prognosis and may prove to be a potential biomarker for treatment selection.
- 8 September 2020
- Published by Springer Nature
- p. 369-422
Digestive System Disease and Sudden Death
Although sudden death caused by digestive system diseases, accounting for about 7% of sudden death diseases, is not common compared with other diseases such as cardiovascular disease, it is also worthy of attention. Among them, sudden death caused by acute pancreatitis is the most common, accounting for 0.2%-0.5% of natural sudden death, and is one of the important causes of non-cardiac sudden death. This chapter mainly focuses on a series of sudden death related digestive system diseases, including ischemic bowel disease, variceal upper gastrointestinal bleeding in cirrhotic portal hypertension, hepatic encephalopathy, liver failure, acute suppurative cholangitis and acute pancreatitis. This type of disease is characterized by a rapid onset, a rapid progress, and a high mortality rate. Combining typical cases, this chapter describes the pathogenesis, diagnosis and treatment progress of the above-mentioned diseases that may cause sudden death.
- 8 September 2020
- Published by Springer Nature
- p. 369-422
Digestive System Disease and Sudden Death
Although sudden death caused by digestive system diseases, accounting for about 7% of sudden death diseases, is not common compared with other diseases such as cardiovascular disease, it is also worthy of attention. Among them, sudden death caused by acute pancreatitis is the most common, accounting for 0.2%-0.5% of natural sudden death, and is one of the important causes of non-cardiac sudden death. This chapter mainly focuses on a series of sudden death related digestive system diseases, including ischemic bowel disease, variceal upper gastrointestinal bleeding in cirrhotic portal hypertension, hepatic encephalopathy, liver failure, acute suppurative cholangitis and acute pancreatitis. This type of disease is characterized by a rapid onset, a rapid progress, and a high mortality rate. Combining typical cases, this chapter describes the pathogenesis, diagnosis and treatment progress of the above-mentioned diseases that may cause sudden death.
- 28 March 2019
- Published by SAGE Publications in American Journal of Hospice and Palliative Medicine®
- Vol. 36 (10) , 900-906
Utilization of Palliative Care for Patients Undergoing Hematopoietic Stem Cell Transplantation During Hospitalization: A Population-Based National Study
Objective: Patients undergoing hematopoietic stem cell transplantation (HSCT) have substantial physical and psychological symptoms. This study aimed to investigate the utilization of palliative care (PC) in patients undergoing HSCT during hospitalization. Methods: The 2008-2014 National Inpatient Sample was queried for eligible participants. Demographics, hospital characteristics, comorbidities, posttransplantation complications, and inpatient procedures were compared between patients with and without PC. Multivariate logistic regression was performed to identify predictors associated with PC use. Results: Among 21 458 patients undergoing HSCT during hospitalization, 278 (1.30%) received PC. The rate of PC use has significantly increased from 0.64% in 2008 to 1.95% in 2014. Patients receiving PC had more co-comorbidities, posttransplantation complications, inpatient procedures, and were more likely to carry a diagnosis of leukemia. In allogeneic HSCT, large bed size (odds ratio [OR] =2.80; 95% confidence interval [CI]: 1.17-6.70), stem cell source from cord blood (OR = 1.93; 95% CI: 1.15-3.24), and graft-versus-host disease (OR = 2.04; 95% CI: 1.36-3.06) were predictors of PC use. In a subset analysis of 783 patients who died during hospitalization, 166 (21.20%) received PC. Among the decedents, Hispanic race had lower odds of PC use (OR = 0.20; 95% CI: 0.05-0.82) in allogeneic HSCT and women had higher odds of PC (OR = 2.70; 95% CI: 1.35-5.41) in autologous HSCT. Conclusions: The rate of PC use has significantly increased among patients undergoing HSCT during hospitalization from 2008 to 2014 but still remains very low. Further investigation is warranted to verify and better understand the barriers toward PC use for HSCT patients.
- 28 March 2019
- Published by SAGE Publications in American Journal of Hospice and Palliative Medicine®
- Vol. 36 (10) , 900-906
Utilization of Palliative Care for Patients Undergoing Hematopoietic Stem Cell Transplantation During Hospitalization: A Population-Based National Study
Objective: Patients undergoing hematopoietic stem cell transplantation (HSCT) have substantial physical and psychological symptoms. This study aimed to investigate the utilization of palliative care (PC) in patients undergoing HSCT during hospitalization. Methods: The 2008-2014 National Inpatient Sample was queried for eligible participants. Demographics, hospital characteristics, comorbidities, posttransplantation complications, and inpatient procedures were compared between patients with and without PC. Multivariate logistic regression was performed to identify predictors associated with PC use. Results: Among 21 458 patients undergoing HSCT during hospitalization, 278 (1.30%) received PC. The rate of PC use has significantly increased from 0.64% in 2008 to 1.95% in 2014. Patients receiving PC had more co-comorbidities, posttransplantation complications, inpatient procedures, and were more likely to carry a diagnosis of leukemia. In allogeneic HSCT, large bed size (odds ratio [OR] =2.80; 95% confidence interval [CI]: 1.17-6.70), stem cell source from cord blood (OR = 1.93; 95% CI: 1.15-3.24), and graft-versus-host disease (OR = 2.04; 95% CI: 1.36-3.06) were predictors of PC use. In a subset analysis of 783 patients who died during hospitalization, 166 (21.20%) received PC. Among the decedents, Hispanic race had lower odds of PC use (OR = 0.20; 95% CI: 0.05-0.82) in allogeneic HSCT and women had higher odds of PC (OR = 2.70; 95% CI: 1.35-5.41) in autologous HSCT. Conclusions: The rate of PC use has significantly increased among patients undergoing HSCT during hospitalization from 2008 to 2014 but still remains very low. Further investigation is warranted to verify and better understand the barriers toward PC use for HSCT patients.
- 1 November 2017
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 26 (11) , 2494-2500
Hospital-Based Study of the Frequency and Risk Factors of Stroke Recurrence in Two Years in China
- 1 November 2017
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 26 (11) , 2494-2500
Hospital-Based Study of the Frequency and Risk Factors of Stroke Recurrence in Two Years in China